Home » Reports » Broker Ratings » Hikma Pharmaceuticals Plc 9.8% Potential Upside Indicated by Barclays Capital

Hikma Pharmaceuticals Plc 9.8% Potential Upside Indicated by Barclays Capital

Hikma Pharmaceuticals Plc using EPIC/TICKER code (LON:HIK) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘EQUAL WEIGHT’ today by analysts at Barclays Capital. Hikma Pharmaceuticals Plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set their target price at 1800 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 9.8% from the opening price of 1639.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 75.5 points and decreased 91 points respectively. The 52 week high for the share price is currently at 2089 GBX while the 52 week low is 1078 GBX.

Hikma Pharmaceuticals Plc has a 50 day moving average of 1,662.05 GBX and a 200 Day Moving Average share price is recorded at 1,737.63. There are currently 241,467,737 shares in issue with the average daily volume traded being 675,090. Market capitalisation for LON:HIK is £4,060,279,997 GBP.

Follow this article (for updates)
X

Follow this article (for updates)

E-mail : *
* Your personal data will be used to support your experience throughout this website and for other purposes described in our Privacy Policy. I hereby agree and consent to the privacy policy.